DUBLIN, March 9, 2018 /PRNewswire/ --
The "Immunofluorescence Assay Market by Product (Reagent, Primary & Secondary Antibody, Imaging Equipment, Immunofluorescence Microscopy), Type (Direct, Indirect), Disease (Cancer, Cardiovascular, Infectious Disease) & End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global immunofluorescence assay market is projected to reach USD 2.01 Billion by 2023 from USD 1.51 Billion in 2018, at a CAGR of 5.8%.
The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare expenditure are the major factors driving the growth of the significant growth drivers of the immunofluorescence assay market. However, high cost of instruments and implementation of excise duty by the US government are expected to limit the growth of immunofluorescence assay market during the forecast period.
On the basis of product, the immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables & accessories. The kits segment is expected to register the highest CAGR during the forecast period. The growth of this segment is primarily attributed to the increasing demand for complete solutions from a single-provider, the rising prevalence of a number of diseases, increasing R&D spending, and increased government funding for life science research.
On the basis of type, the immunofluorescence assay market is segmented into indirect and direct immunofluorescence. The indirect immunofluorescence segment accounted for the largest share and it is also expected to register the highest CAGR during the forecast period. Factors contributing for its high growth include its advantages over direct immunofluorescence, such as sensitivity, flexibility, and lower cost.
Based on disease, the immunofluorescence assay market is segmented into cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, and other diseases (kidney diseases, neurological diseases, skin diseases, gastrointestinal diseases, and oral diseases). In 2017, the cancer segment accounted for the largest share in the global immunofluorescence assay market owing to the increasing prevalence of cancer across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.
On the basis of end user, the immunofluorescence assay market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostics centers, and contract research organizations (CROs). The hospitals and diagnostic centers segment is expected to register the highest CAGR during the forecast period owing to the increasing use of immunofluorescence assay in the diagnose or identify of various diseases.
North America held the largest share of the global immunofluorescence assay market in 2017. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing R&D spending, rising prevalence of diseases, large population in countries such as China and India, improving healthcare infrastructure, increasing healthcare spending, and government initiatives in this region.
The prominent players in the global immunofluorescence assay market are Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinElmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).
Key Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases
- Increasing R&D Spending
- Increasing Healthcare Spending
Restraints
- High Cost of Instruments
- Implementation of Excise Duty by the US Government
Opportunities
- High Growth Opportunities in Emerging Markets
Challenges
- Quality Concerns Over Research Antibodies
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Immunofluorescence Assay Market, by Product
7 Immunofluorescence Assay Market, by Type
8 Immunofluorescence Assay Market, by Disease
9 Immunofluorescence Assay Market, by End User
10 Immunofluorescence Assay Market, by Region
11 Competitive Landscape
12 Company Profiles
- Abcam PLC
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- Danaher Corporation
- Inova Diagnostics (A Part of Werfern Company)
- Medipan GmbH
- Merck Millipore
- Perkinelmer Inc.
- Sino Biological Inc.
- Thermo Fisher Scientific Inc.
- Vector Laboratories (A Part of Maravai Lifesciences)
For more information about this report visit https://www.researchandmarkets.com/research/63qj6v/global?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-immunofluorescence-assay-market-2018-2023-by-product-type-disease-and-end-user---quality-concerns-over-research-antibodies-300611489.html
SOURCE Research and Markets
Share this article